Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Fléjou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Hoefler G, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G, Ensari A. van Krieken JH, et al. Among authors: tejpar s. Virchows Arch. 2008 Nov;453(5):417-31. doi: 10.1007/s00428-008-0665-y. Epub 2008 Sep 18. Virchows Arch. 2008. PMID: 18802721 Review.
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F. Roth AD, et al. Among authors: tejpar s. J Clin Oncol. 2010 Jan 20;28(3):466-74. doi: 10.1200/JCO.2009.23.3452. Epub 2009 Dec 14. J Clin Oncol. 2010. PMID: 20008640 Clinical Trial.
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.
Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H, Harkin DP, Kennedy R, Ilyas M, Morreau H, Proutski V, Swanton C, Tomlinson I, Delorenzi M, Fiocca R, Van Cutsem E, Roth A. Tejpar S, et al. Oncologist. 2010;15(4):390-404. doi: 10.1634/theoncologist.2009-0233. Epub 2010 Mar 29. Oncologist. 2010. PMID: 20350999 Free PMC article. Review.
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.
Troiani T, Vecchione L, Martinelli E, Capasso A, Costantino S, Ciuffreda LP, Morgillo F, Vitagliano D, D'Aiuto E, De Palma R, Tejpar S, Van Cutsem E, De Lorenzi M, Caraglia M, Berrino L, Ciardiello F. Troiani T, et al. Among authors: tejpar s. Br J Cancer. 2012 May 8;106(10):1648-59. doi: 10.1038/bjc.2012.129. Br J Cancer. 2012. PMID: 22569000 Free PMC article.
A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations.
Xie T, D' Ario G, Lamb JR, Martin E, Wang K, Tejpar S, Delorenzi M, Bosman FT, Roth AD, Yan P, Bougel S, Di Narzo AF, Popovici V, Budinská E, Mao M, Weinrich SL, Rejto PA, Hodgson JG. Xie T, et al. Among authors: tejpar s. PLoS One. 2012;7(7):e42001. doi: 10.1371/journal.pone.0042001. Epub 2012 Jul 31. PLoS One. 2012. PMID: 22860045 Free PMC article.
A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency.
Tian S, Roepman P, Popovici V, Michaut M, Majewski I, Salazar R, Santos C, Rosenberg R, Nitsche U, Mesker WE, Bruin S, Tejpar S, Delorenzi M, Bernards R, Simon I. Tian S, et al. Among authors: tejpar s. J Pathol. 2012 Dec;228(4):586-95. doi: 10.1002/path.4092. Epub 2012 Oct 12. J Pathol. 2012. PMID: 22926706 Free PMC article.
255 results